Vishnupriyan Kumar

Mr. Vishnupriyan Kumar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SGShashi Gujar
Shashi Gujar
JPJonathan G. Pol
Jonathan G. Pol
VKVishnupriyan Kumar
Vishnupriyan Kumar
MLManuela Lizarralde-Guerrero
Manuela Lizarralde-Guerrero
PKPrathyusha Konda
Prathyusha Konda
JBJohn C Cameron Bell
John C Cameron Bell

10 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
VKVishnupriyan Kumar
Vishnupriyan Kumar
MGMichael Giacomantonio
Michael Giacomantonio
SGShashi Gujar
Shashi Gujar
Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinically favorable antitumor T cell responses that form protective immunological memory against cancer relapse. This two-prong attack by reovirus on cancers constitutes the foundation of its use as an anticancer oncolytic agent. Unfortunately, the efficacy of these reovirus-driven antitumor effects is influenced by the highly suppressive tumor microenvironment (TME). In particular, the myeloid cell populations (e.g., myeloid-derived suppressive cells and tumor-associated macrophages) of highly immunosuppressive capacities within the TME not only affect oncolysis but also actively impair the functioning of reovirus-driven antitumor T cell immunity. Thus, myeloid cells within the TME play a critical role during the virotherapy, which, if properly understood, can identify novel therapeutic combination strategies potentiating the therapeutic efficacy of reovirus-based cancer therapy.

12 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NDNehanjali Dwivedi
Nehanjali Dwivedi
SMSreejeta Mondal
Sreejeta Mondal
SPSmitha PK
Smitha PK
STSowmya T.
Sowmya T.
KSKartik Sachdeva
Kartik Sachdeva
MDManjula Das
Manjula Das
Dysregulation of BCL2 is a pathophysiology observed in haematological malignancies. For implementation of available treatment-options it is preferred to know the relative quantification of BCL2 mRNA with appropriate reference genes. For the choice of reference genes—(i) Reference Genes were selected by assessing variation of >60,000 genes from 4 RNA-seq datasets of haematological malignancies followed by filtering based on their GO biological process annotations and proximity of their chromosomal locations to known disease translocations. Selected genes were experimentally validated across various haematological malignancy samples followed by stability comparison using geNorm, NormFinder, BestKeeper and RefFinder. (ii) 43 commonly used Reference Genes were obtained from literature through extensive systematic review. Levels of BCL2 mRNA was assessed by qPCR normalized either by novel reference genes from this study or GAPDH, the most cited reference gene in literature and compared. The analysis showed PTCD2, PPP1R3B and FBXW9 to be the most unregulated genes across lymph-nodes, bone marrow and PBMC samples unlike the Reference Genes used in literature. BCL2 mRNA level shows a consistent higher expression in haematological malignancy patients when normalized by these novel Reference Genes as opposed to GAPDH, the most cited Reference Gene. These reference genes should also be applicable in qPCR platforms using Taqman probes and other model systems including cell lines and rodent models. Absence of sample from healthy-normal individual in diagnostic cases call for careful selection of Reference Genes for relative quantification of a biomarker by qPCR.BCL2 can be used as molecular diagnostics only if normalized with a set of reference genes with stable yet low levels of expression across different types of haematological malignancies.